Fulcrum Therapeutics Fair Value Estimate Rises to $5.83 After Pociredir Exit

Analyst

โดย Simply Wall St·

Summary · why it matters

Simply Wall St has raised its Fair Value estimate for Fulcrum Therapeutics to US$5.83 per share from US$5.43, reflecting updated analyst assumptions after the company discontinued its sickle cell disease drug pociredir. The revision incorporates a higher projected revenue growth rate of 216.56%, an improved net profit margin expectation of 21.87%, and a lower future price-to-earnings multiple of 96.08 times, while the discount rate remained at 7.11%. The adjustment comes as multiple Wall Street firms, including Piper Sandler, BofA, Stifel, Truist, H.C. Wainwright, and Leerink, cut ratings and set price targets in a US$3 to US$4 range, with Goldman Sachs suspending its rating and JPMorgan moving to Underweight. Analysts now focus on Fulcrum's cash-rich balance sheet, with Truist estimating cash at about US$4 per share, and on the ongoing strategic review rather than late-stage pipeline potential.

Fulcrum Therapeutics Inc ▼